Suppr超能文献

在非清髓性造血细胞移植后第 7 天肿瘤坏死因子受体 1 升高与急性移植物抗宿主病。

Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

机构信息

Division of Hematology, Department of Medicine, CHU of Liége, Liége, Belgium.

出版信息

Bone Marrow Transplant. 2010 Sep;45(9):1442-8. doi: 10.1038/bmt.2009.360. Epub 2010 Jan 11.

Abstract

Acute GVHD has remained a significant cause of nonrelapse mortality after allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning. The role of TNF-alpha in the biology of acute GVHD after nonmyeloablative conditioning has not been studied thus far. Here, we measured TNF receptor 1 (TNFR1) as a surrogate marker for TNF-alpha in 106 patients before the start of the conditioning regimen (baseline) and 7 days after allogeneic HCT with nonmyeloablative conditioning. The nonmyeloablative regimen consisted of 2 Gy TBI alone (n=15), 2 Gy TBI plus fludarabine 90 mg/m2 (n=73), or 4 Gy TBI plus fludarabine 90 mg/m2 (n=18). TNFR1 levels increased significantly from baseline to day 7 after nonmyeloablative HCT (P<0.0001). Patients conditioned with 4 Gy TBI had higher TNFR1 day 7/baseline ratio than those conditioned with 2 Gy TBI (median 1.65 versus 1.25; P=0.01). In a multivariate Cox model, high TNFR1 day7/baseline ratio was associated with grades II-IV (HR=2.2, P=0.01) and grades III-IV (HR=2.9, P=0.007) acute GVHD, but had no impact on overall survival (P=0.8). In summary, our data suggest that nonmyeloablative conditioning induces the generation of TNF-alpha, and that the magnitude of TNF-alpha generation depends on the conditioning intensity (2 Gy versus 4 Gy TBI). Further, assessment of TNFR1 levels before and on day 7 after nonmyeloablative HCT provided useful information on subsequent risk of experiencing acute GVHD.

摘要

急性移植物抗宿主病(GVHD)仍然是异基因造血细胞移植(HCT)后非复发死亡率的重要原因,而非清髓性预处理条件下。迄今为止,尚未研究 TNF-α 在非清髓性预处理后急性 GVHD 生物学中的作用。在这里,我们在 106 例患者开始预处理方案(基线)前和非清髓性 HCT 后 7 天测量 TNF 受体 1(TNFR1)作为 TNF-α的替代标志物,非清髓性方案包括单独 2 Gy TBI(n=15)、2 Gy TBI 加氟达拉滨 90mg/m2(n=73)或 4 Gy TBI 加氟达拉滨 90mg/m2(n=18)。非清髓性 HCT 后,TNFR1 水平从基线显着升高至第 7 天(P<0.0001)。与接受 2 Gy TBI 预处理的患者相比,接受 4 Gy TBI 预处理的患者第 7 天/TNFR1 基线比值更高(中位数 1.65 比 1.25;P=0.01)。在多变量 Cox 模型中,高 TNFR1 第 7 天/基线比值与 II-IV 级(HR=2.2,P=0.01)和 III-IV 级(HR=2.9,P=0.007)急性 GVHD 相关,但对总生存无影响(P=0.8)。总之,我们的数据表明,非清髓性预处理诱导 TNF-α 的产生,并且 TNF-α 的产生程度取决于预处理强度(2 Gy 与 4 Gy TBI)。此外,非清髓性 HCT 前后和第 7 天 TNFR1 水平的评估提供了有关随后发生急性 GVHD 风险的有用信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验